Caribou Biosciences, Inc. CRBU

About Caribou Biosciences, Inc. (CRBU): stock profile, AI score and financials

Caribou Biosciences, Inc. (CRBU) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRBU at 13.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,841 of 2,925 stocks — the bottom half of the AI-ranked universe. CRBU scores in the top quartile across institutional flow (83.2). Areas of concern include free cash flow (2.0) and profitability (2.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Caribou Biosciences, Inc. reports quarterly revenue of $1.5M, net income of $-24.3M, free cash flow of $-22.8M. Top institutional holders of CRBU by reported 13-F value include BlackRock, PFIZER, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CRBU trades on the Nasdaq exchange and files with the SEC under CIK 1619856. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRBU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Caribou Biosciences, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1619856 →